

### NIH Public Access

**Author Manuscript** 

J Int Neuropsychol Soc. Author manuscript; available in PMC 2013 February 15.

### Published in final edited form as:

J Int Neuropsychol Soc. 2013 January; 19(1): 73–87. doi:10.1017/S1355617712000938.

### Identification of Mild Cognitive Impairment in ACTIVE: Algorithmic Classification and Stability

Sarah E. Cook<sup>1,2</sup>, Michael Marsiske<sup>2</sup>, Kelsey R. Thomas<sup>2</sup>, Frederick W. Unverzagt<sup>3</sup>, Virgina G. Wadley<sup>4</sup>, Jessica B. S. Langbaum<sup>5</sup>, and Michael Crowe<sup>5</sup> <sup>1</sup>Department of Medicine, Duke University, Durham, North Carolina

<sup>2</sup>Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida <sup>3</sup>Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana <sup>4</sup>Department of Psychology, University of Alabama-Birmingham, Birmingham, Alabama

<sup>5</sup>Banner Alzheimer's Institute, Banner Health, Phoenix, Arizona

### Abstract

Rates of mild cognitive impairment (MCI) have varied substantially, depending on the criteria used and the samples surveyed. The present investigation used a psychometric algorithm for identifying MCI and its' stability to determine if low cognitive functioning was related to poorer longitudinal outcomes. The Advanced Cognitive Training of Independent and Vital Elders (ACTIVE) study is a multi-site longitudinal investigation of long-term effects of cognitive training with older adults. ACTIVE exclusion criteria eliminated participants at highest risk for dementia (i.e., MMSE<23). Using composite normative for sample- and training- corrected psychometric data, 8.07% of the sample had amnestic impairment, while 25.09% had a non-amnestic impairment at baseline. Poorer baseline functional scores were observed in those with impairment at the first visit, including a higher rate of attrition, depressive symptoms, and self-reported physical functioning. Participants were then classified based upon the stability of their classification. Those who were stably impaired over the five-year interval had the worst functional outcomes (e.g., IADL performance), and inconsistency in classification over time also appeared to be associated increased risk. These findings suggest that there is prognostic value in assessing and tracking cognition to assist in identifying the critical baseline features associated with poorer outcomes.

### Keywords

cognitive impairment; research classification; cognitive aging; longitudinal follow-up

For a subset of older adults, cognitive abilities decline more than normal, which may be the first indication of a pathological condition. There have been many terms for such decline (e.g., age-related cognitive decline, age-associated memory impairment [American Psychiatric Association, 1994], and cognitive impairment no dementia [CIND; Ebly, Hogan & Parhad, 1995; Graham, Rockwood & Beattie, 1997]), but the most widely recognized diagnostic category is mild cognitive impairment (MCI; Petersen et al., 1999). While early research focused on amnestic MCI (Petersen, 1995), where memory is the only domain of

Correspondence regarding this manuscript should be addressed to Michael Marsiske, Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, 32610-0165, Phone (352) 273-5097, marsiske@ufl.edu. There were no conflicts of interest.

cognitive impairment, a broadened conception has been advocated (Petersen, 2004) and includes classifications for single- and multiple-domain non-memory impairments, under an assumption that different neurodegenerative disorders may present with different patterns of cognitive symptoms. Petersen's criteria (2004) include a requirement for unimpaired daily functioning, subjective cognitive complaint, and an exclusion of dementia. These criteria are somewhat flexible, as they do not specify which instruments should be utilized to examine each of these criteria. Additionally, performance cutoffs vary by study, often ranging from 1-2 standard deviations below the mean (Jak et al., 2009). Because of this flexibility, the classification of MCI across studies has varied widely (e.g., Busse, Bischkopf, Riedel-Heller & Angermeyer, 2003; Caracciolo, Gatz, Xu, Pedersen & Fratiglioni, 2012; Tuokko & McDowell, 2006). Jak and colleagues (2009) demonstrated that varying classification criteria yielded results of 10-74% of their sample being characterized as having MCI. The International Working Group's (Winblad et al., 2004) recommendations for MCI criteria closely resembled Petersen's (2004), with the exception of not requiring a subjective cognitive complaint in lieu of concerns voiced by a collateral. The subjective complaint component is somewhat controversial and was not included in the current study, in part because of concerns about low validity of complaints (Cook & Marsiske, 2006), limited utility due to confounding factors like overlying depression and impaired awareness (Crowe et al., 2006; DeJager, Blackwell, Budge & Sahakian, 2005; Jorm et al., 1997), and the existence of several studies that have shown that cognitive complaints are poor predictors of progression (Blazer, Hays, Fillenbaum & Gold, 1997; Busse et al., 2003; Fisk, Merry & Rockwood, 2003; Jorm et al., 1997; Palmer, Backman, Winblad & Fratiglioni, 2003).

In addition to concerns about subjective complaints, there have also been questions raised about the inclusion of unimpaired daily functioning. There has not been consensus on which functions to measure (Panza et al., 2005). Marsiske and Margrett (2006), for example, reviewed a large number of studies finding that cognitive measures of everyday functioning —particularly those emphasizing Instrumental Activities of Daily Living (IADL's; e.g., finances, managing medication regimens)—do in fact discriminate persons with MCI from normal older adults. It is important, however, to distinguish between physical and cognitive sources of functional impairment, since the later is more likely to be dementia-related. Previous work from the ACTIVE study suggested that being classified in any MCI subgroup (amnestic, non-amnestic, multi-domain) predicted greater three-year decline in both ADL and IADL perceived difficulty and performance (Wadley et al., 2007). While there was very little variability in baseline ADL/IADL of ACTIVE participants due to the inclusion criteria described below, measuring changes over time may serve as an important variable in determining what factors may be predictive of poor outcomes in MCI.

Many MCI investigations to date have been clinical studies, where participants are selfselected and most often already have cognitive complaints (Feldman & Jacova, 2005; Panza et al., 2005). Extending the MCI concept to community-based population studies can be challenging due to the feasibility and cost associated with a full clinical and neuropsychological assessment to determine MCI status. While several prospective studies have utilized consensus classification of MCI (e.g., Busse et al., 2003; Fisk, Merry & Rockwood, 2003; Jorm et al., 1997; Manly et al., 2005; Manly et al., 2008; Unverzagt et al., 2001; Unverzagt et al., 2011), the use of a novel algorithmic (test-based) classification approach has also been examined. For example, Ganguli et al. (2010) used an algorithmic approach to determine the prevalence of MCI using different classification criteria. When classification was based solely on cognitive performance, using a cutoff of 1 standard deviation below the sample mean, 35% of their sample was classified with MCI. Ritchie, Artero and Touchon (2001) retrospectively identified amnestic MCI in a French populationbased study that included a computerized neuropsychological battery, as well as subjective complaint and daily function measures.

The goal of this paper, consistent with the work of Ganguli et al. (2004, 2010) and Ritchie, Artero and Touchon (2001), was to study the five-year outcome of retrospectively-identified cognitive, cognitively low functioning, at-risk participants of the ACTIVE (Advanced Cognitive Training of Independent and Vital Elders) study over the first five years of follow-up. The ACTIVE study offers a large, multi-site, well-characterized, and longstudied (soon to be 10 years) cohort, thus offering a unique opportunity to examine cognitive aging outcomes that many other studies may not be equipped to examine. However, a limitation, as discussed in more detail below, is that the study did not employ standard clinical measures and procedures to classify participants. While cognitive domains were created to be roughly analogous to those used by Jak et al. (2009), the measures do not perfectly correspond. While not conforming to the exact clinical MCI criteria (e.g., Petersen et al., 1999), multiple forms of low cognitive functioning were identified using a psychometric algorithm approach outside the usual clinical context, rather than via a clinical consensus. Since outcomes of MCI are complex, input from a variety of samples and definitional methodologies may assist in identifying the critical baseline MCI features that predict poor outcomes or morbidity. While other studies of MCI have examined long-term outcomes such as conversion to dementia, nursing home placement, and death (e.g., Storandt, Grant, Miller & Morris, 2002; Ganguli et al., 2004; Artero et al., 2008), we examined differences in group characteristics, including baseline functional (ADL/IADL) status, general self-reported health, and depression. We also explored differences in progression to incident dementia based on estimates derived by Unverzagt et al. (2012) and attrition, as failure to continue to participate may be informative of one's broader functional and/or motivational status at the time of withdrawal. Lastly, the stability of classifications over the 5-year interval was determined by group with a focus on examining the differences in functional outcomes for those that remained stably impaired versus those with variability in classification.

### Method

### **Participants**

All participants (N = 2802) randomized in the ACTIVE clinical trial were considered for cognitive impairment classification. Recruitment procedures, sample characteristics, and study design have been described elsewhere (Ball et al., 2002; Willis et al., 2006). Briefly, the randomized, controlled, single-blind trial evaluated the effectiveness of three cognitive training interventions in improving mental abilities and daily functioning in independent adults over age 65. Inclusion criteria required participants to have a Mini-Mental State Exam (MMSE; Folstein, Folstein & McHugh, 1975) score of 23, no prior diagnosis of dementia, and no self-reported ADL limitations (e.g., bathing, dressing, and personal hygiene). Participants were recruited at six field sites and included over-sampling of African Americans. All procedures were approved by the Institutional Review Boards at each collaborating site and informed consent was obtained prior to participation.

For the larger ACTIVE intervention study, participants were randomized into one of four training conditions, and half of the trained participants were subsequently randomized to receive additional booster training. This resulted in seven experimental groups (Control, Memory, Memory+Booster, Reasoning, Reasoning+Booster, Speed, Speed+Booster; see Willis et al., 2006). The current study did not examine training effects, but these groupings were employed to adjust for differential rates of change at later occasions, as described below.

Analyses examined cognitive impairment at each of the study occasions except the immediate posttest (baseline, BL; first annual, A1; second annual, A2; third annual, A3; fifth annual; A5; there was no fourth annual assessment), as well as the association between

stability of impairment and selected outcomes over all possible temporal sequences (1-, 2-, 3, 4- and 5-years). The five-year stability information was largely similar to that of all shorter sequences, so for the purposes of parsimony the BL-to-A5 sequence is the focus of this paper. At baseline, all 2,802 participants were included in analyses. A total of 1877 participants returned for A5 (56.3% retention rate) and 66 participants were not classified due to missing cognitive data resulting in an analytical sample of 1811 at A5. Group differences in rates and type of attrition are presented in the results section below.

### Measures

**Description of domains and measures**—Cognitive measures in ACTIVE were selected as cognitive endpoints for the intervention study (i.e., did trained participants improve ?) or for screening/sample characterization purposes. ACTIVE did not include a standard neuropsychological battery or standard administration for all measures. At the same time, ACTIVE did employ a robust battery of individual differences measures to permit the longitudinal characterization of the sample. Following Jak et. al. (2009), the cognitive measures for this study were categorized into five major domains: Memory, Attention, Language, Visuospatial Processing Speed, and Complex Cognition. (The latter category deviates from Jak's "executive functioning" domain, but better reflects the measures given in ACTIVE). Measures for each domain are shown in Table 1, along with a description of their administration conditions.

Additional measures were used to compare group differences at baseline and follow-up. These include the Mini-Mental State Exam (MMSE) to measure global functioning (Folstein et al., 1975), and the Center for Epidemiological Studies-Depression-12 scale (CES-D) to assess depressive symptomotology (Radloff, 1977). A composite of everyday functioning that is composed of the sum of the Instrumental Activities of Daily Living (IADL) performance and difficulty scores and Activities of Daily Living (ADL) score (ADL/IADL Morris et al., 1997) was used as a tool to examine functional status (higher scores=lower functioning). The Physical Functioning and General Health subscales of the MOS Short Form Health Survey (SF-36; Ware & Sherbourne, 1992) were used to evaluate general wellbeing that is non-specific to cognition.

### Procedures

**Classification of participants**—The baseline data were used as the basis for the percentiling of all scores at all occasions. Percentiles were used (versus a standard-deviation-unit cutoff) to guard against possible non-normality of scores. The baseline score distribution for each measure was computed separately for each combination of age (65–69.9, 70–74.9, 75–79.9, and 80+ years), education (0–11.9 years, 12–15.9 years, and 16+ years), and race (African American, White).

At occasions after baseline, raw scores were first adjusted for practice/training effects, and then were percentiled according to each participant's baseline subgroup distribution. For example, if a participant was randomized into the "reasoning+booster training group", then the average later-occasion gain experienced by that group was subtracted from the participant's followup score. So, if the reasoning+booster training group, on average, had a baseline score of 12, 14 at A1, and 16 at A2, then the group's net gain at A1 and A2 were 2.0 and 4.0 points, respectively. These net gains were subtracted from every reasoning +booster participant to rescale their later scores back into baseline metric. This rescaling was done separately for every measure, at every occasion, and for each of the seven groups listed above. This approach corrected for gross training and practice effects, but still allowed individuals who gained more or less than their group to preserve their differential changes. It was these adjusted scores that were percentiled against an individual's age-race-education

baseline subgroup's distribution. Once all tests were percentiled at all occasions, then composite percentile scores (mean of each individual test's percentile) were computed in each of the five cognitive domains (Memory, Attention, Language, Visuospatial Processing Speed, Complex Cognition) at each occasion. Individuals whose average percentile was 15.87 or lower (~1 SD below the mean) were classified as impaired in that domain.

Using these domain percentiles, participants were then classified into three groups: <u>Unimpaired</u>, <u>Amnestic MCI</u>, and <u>Non-Amnestic MCI</u>. At each occasion, participants were considered Amnestic if they were considered impaired in the Memory domain, and Non-Amnestic if they were impaired in one or more of the other four domains (Attention, Language, Visuospatial Processing Speed, Complex Cognition) and not Memory. While these classifications use similar terminology to Petersen (2004), subjective memory complaints were not considered. Given ceiling effects in daily functioning at baseline (due to ACTIVE inclusion criteria), there was no exclusion criterion for functional impairments in the current study. Not having done so at baseline, we also did not do so at later classifications, so as not to disrupt the stability of our classification algorithm. ADL/IADL differences are considered, however, in our group comparisons below.

Intraindividual stability of classification-For every combination of occasions (i.e., BL-to-A1, BL-to-A2, BL-to-A3, BL-to-A5, A1-to-A2, etc.), participants were classified into six groups based on the stability of their impairment classification at each respective occasion (Amnestic, Non-Amnestic, Unimpaired). As noted above, given the similarity of findings across occasions, only data from BL to A5 (the longest possible sequence) are presented here; shorter sequences are presented in the Appendix. Participants were considered (1) Stable Amnestic (AMNESTIC) if they were classified as Amnestic at both respective occasions (e.g., BL and A5); (2) Stable Non-Amnestic (NON) if they were classified as Non-Amnestic at both occasions; (3) Flipped Impairment (FLIP) if they were impaired at both occasions, but whose impairment classification switched (i.e., from Amnestic-to-Non-Amnestic or Non-Amnestic-to-Amnestic); (4) Reverted to Unimpaired (REVERT) if the participant was impaired at the first occasion (e.g., BL)but then were unimpaired at the second occasion (e.g., A5); (5) Worsened to Impaired (WORSEN) if they were first classified as Unimpaired but then were impaired at the second occasion being examined; and (6) Stable Unimpaired (UNIMPAIRED) if the participant was consistently Unimpaired across the respective occasions being investigated. If a participant was not present at one of the two occasions being examined, then they were not included in those specific classification analyses.

**Attrition**—Overall study attrition was examined and defined as not being present at A5 (they may have dropped out at any point during the intervening five years). Followup attrition analyses examined differences between baseline impairment groups in subtypes of attrition (using categories first described by Cooney, Schaie & Willis, 1988), including voluntary (not motivated/interested, no time, moved or lost-to-follow-up, unresponsive, non-compliant, or for unspecified reasons), involuntary (relocation, too sick, caregiving demands, moved to nursing home, dementia, or family refuses access), and death.

### **Statistical Analyses**

Demographic comparisons between groups were conducted with Bonferroni-corrected oneway ANOVAs for continuous variables. Chi-square analysis was used for dichotomous variables, with logistic regressions (unimpaired group as reference group) as Bonferronicorrected follow-ups. Subsequent analyses compared the six intraindividual stability groups on A5 outcomes. As with the baseline comparisons, Bonferroni-corrected one-way ANOVAS and or Chi-square analyses were conducted. To test whether reasons for attrition

differed by baseline impairment group we used a Chi-Square Goodness of Fit test, under the equiprobability null hypothesis. This approach enabled us to compare proportions directly, and was not biased by differences in group size.

### Results

Table 2 shows demographic information and various outcomes of the baseline classification of the analytic sample. At baseline, the results indicated that a total of 929 participants met the algorithmic criteria for MCI, with 8.07% of the analytical sample classified with as Amnestic and 25.09% as Non-Amnestic (i.e., impairment in 1+ non-memory domain), resulting in 66.85% of the sample being Unimpaired. Table 3 displays the raw number of participants classified as impaired by specific cognitive domain. While the analyses only distinguished between Amnestic and Non-Amnestic, for the sake of transparency, Table 3 distinguishes between single-domain, mulitdomain—amnestic, and multidomain—non-amnestic.

Comparing the impairment groups (Table 2; to adjust for possible sources of group differences, vision and depression were covaried), several significant group differences were found. Specifically, the Amnestic group was significantly older than the Unimpaired group, despite using age as a stratification variable in the percentiling of individual scores. Neither education nor the proportion of African Americans differed across groups. There was a higher proportion of men in the Amnestic (p<.05) and Non-Amnestic (p<.10) groups. Both of impaired groups performed significantly worse than the Unimpaired group on Vision, depressive symptoms, and the SF-36 Physical Functioning subscale. On the MMSE and the IADL/ADL outcome, a three-group difference emerged (Unimpaired>Non-Amnestic). Since five language items from the MMSE were used as a language domain measure (for the purpose of classification), we re-examined the group differences with the language items removed, and the pattern of group differences was identical. On the SF-36 General Health subscale, the Non-amnestic group rated its health more poorly than the unimpaired group.

### **Incident Dementia and Attrition**

**Differences in progression to dementia status**—As shown in Table 2, chi-square analyses with follow-up logistic regressions revealed that the proportion of participants progressing to dementia status defined by Unverzagt et al. (2012) by A5 was significantly higher in the Amnestic and Non-Amnestic groups than in the Unimpaired group. Combining data from the Amnestic and Non-Amnestic groups, and comparing to the Unimpaired, impaired participants had 3.4 times higher rates of progression to dementia.

**Differences in dropout by impairment group**—Similar to incident dementia, the proportion of participants dropping out of the study by A5 was significantly higher in the Amnestic and Non-Amnestic groups than in the Unimpaired group. When we subsequently examined type of attrition, both impaired groups evinced a higher proportion of dropouts in each category relative to the Unimpaired group. Combining data from the impaired groups and comparing to the Unimpaired, impaired participants had 1.4, 1.6, and 1.7 times higher rates of dropout for reasons of voluntary (i.e., not interested, too busy), involuntary (i.e., relocated, too ill, caregiving), and death, respectively.

### Long-term consequences of stability of impairment status

As noted in the Method section, the results focus on the individual outcomes associated with one's classification stability from BL-to-A5. Due to length limitation and similar findings

compared to the 5-year period, stability for all shorter periods are not discussed here (see Appendix for tables).

Table 4 displays the six different kinds of stability/instability observed in this study. These include: (1) stably amnestic (AMNESTIC), (2) stably non-amnestic (NON), (3) impaired at both occasions but "flipped" from one subtype to another (FLIP), (4) impaired at baseline but were later unimpaired (REVERT), (5) initially unimpaired but progressed to impaired (WORSEN), and (6) stably unimpaired across the period (UNIMPAIRED).

Given the complexity of Table 4, the best general schematic summary of differences is UNIMPAIRED>REVERT>WORSE>NON>FLIP>AMNESTIC. This ordering was fairly consistent across most of the long-term outcomes. Breaking this down, we first examined the three stable groups. Generally, AMNESTIC showed the poorest scores on most outcomes considered although, for reasons of statistical power, differed from the UNIMPAIRED participants only on MMSE and ADL/IADL performance. The NON group showed a similar pattern, evincing poorer performance than the UNIMPAIRED on the MMSE and ADL/IADL. The NON group also had a higher proportion of African Americans than the UNIMPAIRED. Comparing AMNESTIC and NON, the AMNESTIC group showed significantly lower MMSE scores (about 2 scale points).

Next, for groups who experienced classification changes between BL and A5, the REVERT>WORSE>FLIP pattern implied above held for the MMSE, ADL/IADL, SF-36 general health and physical functioning and the CES-D. A small exception to this pattern was seen for vision, where the WORSEN group showed poorer vision than the FLIP group. FLIP and WORSEN groups were significantly older than the UNIMPAIRED, and there was a significantly higher proportion of women in the FLIP group than in the UNIMPAIRED. In general, while performing slightly better on most variables, the FLIP and WORSEN groups were not statistically different from either the AMNESTIC or NON groups.

Taken together, the results suggest that impairment status at any time was associated with poorer long-term outcomes in cognitive, affective, functional and sensory domains, with the least long-term risk for those who appeared to revert to normal. This held despite the fact that impairment classifications were adjusted for age, education and race group membership.

### Discussion

The first aim of this study was to identify MCI participants for each follow-up over the first five years of the study using a psychometric method that solely relied on normative for sample- and training-corrected cognitive performance. At baseline, results indicated a total of 8.07% of the sample had an amnestic impairment, while 25.09% had a non-memory impairment (i.e., impairment in either attention, language, visuospatial processing speed, or complex executive domain). This rate is likely over-inclusive due to the four domains that comprise this group compared to the one domain for the amnestic group, as well as the 1-standard deviation definition of impairment. Nonetheless, it likely identifies community-dwelling individuals with low baseline cognition that may be at risk of further decline. The remaining 66.85% of the sample were not impaired in any domain. Importantly, ACTIVE is not a population-based cohort and since 929 individuals (33.15%) met the criterion for some type of mild impairment at baseline, the current classifications should not be considered incidence rates.

In a prior algorithmic study, Ritchie et al. (2001) found a rate of amnestic MCI of 3.2%, which is lower than the rate of amnestic impairment in the current study, despite having the same 1-SD definition of impairment. The current rate of any impairment is slightly lower than the 35% noted in a population-based study that algorithmically classified MCI using the

same a 1-SD definition as done in the current study (Ganguli et al., 2010). The current rate of cognitive impairment is also similar to previous population estimates (e.g., Plassman et al., 2008; Unverzagt et al., 2001). As such, the similarity of our prevalence rates relative to other investigations lends support to the use of the MCI label in this non-traditional investigation of community-based participants. The between-study differences in rates are likely due to the substantial sampling variations.

Demographic and functional status comparisons at baseline suggested that the Amnestic group was disadvantaged in several ways in comparison to the other groups. Both impaired groups performed worse than the unimpaired group on measures of vision, self-reported physical functioning, and depressive symptoms. Additionally, impaired participants were significantly more likely to progress to dementia status and leave the study over the 5-year interval. There were no significant differences between classification groups on education level or race, likely as a result of controlling for these variables in developing the sample's normative cognitive scores for classification. The magnitude of these differences (Cohen's f: 0.1=small, 0.25=medium, 0.4=large; Cohen, 1988) range from very small for most of the demographic variables (e.g., age, education, general health, physical functioning), to small for IADL/ADL, to medium for the MMSE. The magnitude for the differences in raw test scores ranged from medium (e.g., Digit Symbol Copy) to large (e.g., HVLT).

The group classifications in the current study were somewhat fluid over the five-year interval. In general, those who were stably impaired had poorer long term outcomes across the variables studied (e.g., ADL/IADL, MMSE), lending support to the notion that the baseline impaired participants were likely an at-risk group. Additionally, inconsistency in performance and classification also appeared to be related to poorer outcomes, with those who 'flipped' impairment, as well as those who worsened over time, appeared to have poorer outcomes for almost all outcome variables. Lastly, even the group that reverted from impaired to unimpaired had less favorable 5-year outcomes than those who were stably unimpaired; however, this 'revert' group did have the least poor outcomes of all the impairment groups. The magnitude of these group differences ranged from small for age, education, vision, CES-D, general and physical health, to medium for IADL/ADL functioning, to large for the MMSE. Taken together, it appears that even in a study like ACTIVE, where clinical classification was not the intended goal at the outset of the study, there is prognostic value for identifying and tracking long-term cognitive impairment outcomes.

While no ACTIVE participants met CES-D cutoffs indicative of major depression at enrollment, baseline impaired groups did report a higher number of depressive symptoms compared to the Unimpaired group. Over time, those who worsened and flipped impairment groups appeared to have more depressive symptoms than those who remained stably unimpaired. This is consistent with literature suggesting that there is a higher risk of conversion to MCI when participants initially demonstrate depressive symptoms (Goveas, Espeland, Woods, Wassertheil-Smoller & Kotchen, 2011) and that early-onset and/or chronic depression itself serves as a risk for developing dementia (Panza et al., 2010).

The fluidity of classifications over time is similar to previous studies that have found substantial rates of individuals originally classified as impaired, but subsequently classified as normal on follow-up assessment (for review see Brooks, Iverson, Holdnack & Feldman, 2008). Briefly, such fluidity can result from various factors, such as retrofitting criteria to data that may not have been collected for the purposes of MCI identification, the rigidity of an algorithm whereas small shifts in a test score might not sway clinical consensus panels, the possibility of regression to the mean, as well as an understanding of the base rates of low or 'abnormal' test scores in the population (Brooks, Iverson & White, 2007). It is likely that

the large number of Non-Amnestic participants contributed the instability found in this sample, as the single-domain non-amnestic subtype often displays the lowest stability, with evidence of up to 50% returning to unimpaired status (e.g., Bickel et al., 2006, for review see Jak et al., 2009b). Regardless of the source, the classification variability underscores the importance of multiple assessments for determining the most appropriate treatment action (Feldman & Jacova, 2005).

There are several limitations to this study. First, ACTIVE does not represent a nationallyrepresentative sample. Comparison of the baseline enrollment sample (enrolled between 1998 and 2000) and the 2000 US census (US Census Bureau, 2000) suggests that ACTIVE fairly well represented the proportion of the population of white females and African American males, but slightly over-represented African American females and underrepresented the prevalence of white males. The oldest cohorts were also somewhat underrepresented. Whites in ACTIVE were somewhat more educated than the population, whereas African American participants were substantially more educated than the population. Notably, these differences played little role in individual impairment classifications, since classifications were done separately for age/educational/race subgroups. Importantly, the majority of participants of ACTIVE were in a training program intended to improve their performance. While this factor does add variance in the data that is not present in other published longitudinal MCI studies, a correction factor derived from the average gain for each treatment group was employed in order to adjust for some of this additional variance.

Second, ACTIVE had a high rate of attrition over the five-year interval, and the groups with cognitive impairment had higher rates of attrition compared to the unimpaired elders. However, the analyses in this study suggest that amount and type of attrition (> 1.5 times the rate of involuntary attrition, like illness and relocation, as well as death) was consistent with the notion that those classified as impaired were less able to continue with the demands of the study. Another limitation is that the current study did not employ standard clinical measures and procedures to classify participants as what is typically considered MCI, thus the measures used in the present study might not be the best indicators of impairment. Some cognitive tasks shown in published studies to be affected in MCI patients were not included in the study (e.g., delayed memory free recall, verbal fluency, set-shifting, and visuospatial constructions).

Because of the battery of measures used and the non-standard administration, external published normative information was not appropriate to use. Moreover, classification was based solely on composite test performance standardized to the sample mean after controlling for confounding variables (e.g., age, education, race), which has inherent error and variability that may have led to misclassification, especially for those participants who were close to the cutoff (Larrieu et al., 2002). Next, by relying on a percentile cutoff in our algorithm, this serves to predefine the proportion of participants who will have impairment, which is true of all normative-based approaches. Lastly, the algorithmic approach used in this investigation did not exclude participants who may have cognitive impairment beyond MCI. So as not to compromise the consistency of the algorithm at the fifth annual follow-up, daily functioning was not included at the later occasion. Given the limitations, additional studies utilizing a more standard assessment are needed for replication of findings. It is noteworthy that, despite these limitations, we found clear functional differences between impaired and unimpaired groups (even after age/education/race correction), higher rates of incident dementia and informative dropout in those classified as impaired, and that stable classification as impaired was associated with poorer five-year outcomes. Thus, while the classifications in this study cannot be upheld as meeting a rigorous clinical evaluation standard, we believe that the findings may nonetheless have relevance and interest to a

neuropsychologist audience. ACTIVE offers an unusually large, well-characterized, and long-studied cohort, and therefore offers a naturalistic lens on cognitive changes that many other studies cannot.

Now that classifications have been developed for ACTIVE, future work can further explore the neuropsychological, demographic and medical predictors of the cognitive impairment classifications within this sample, as this study can serve as a lens into how incipient cognitive impairment may play out in a large, community-dwelling cohort. Additionally, these classifications can be used to determine how low initial cognitive functioning may have impacted training gains or other functional outcomes, including driving, medication use, or relocation. This study has shown that other longitudinal cognitive aging studies could potentially have an alternative way of analyzing data that was not specifically collected for the purpose of identifying cognitive impairment to help better understand the complexity of the longitudinal outcomes of MCI from different samples and definitional methodologies to assist in identifying what critical baseline MCI features may predict poorer outcomes.

### Acknowledgments

Supported by grants from the National Institute of Nursing Research (U01 NR04508, U01 NR04507) and the National Institute on Aging (U01 AG14260, U01 AG14282, U01 AG14263, U01 AG14289, U01 AG014276). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research, National Institute on Aging, or the National Institutes of Health. Representatives of the funding agency have been involved in the review of the manuscript but not directly involved in the collection, management, analysis or interpretation of the data. Drs. Unverzagt and Marsiske have received research support from Posit Science, Inc., in the form of site licenses for cognitive training programs for different research projects.

### References

- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Association Press; 1994.
- Artero S, Ancelin M-L, Portet F, Dupuy A, Berr C, Dartigues J-F, Tzourio C, Ritchie K. Risk Profiles for Mild Cognitive Impairment and Progression to Dementia Are Gender Specific. Journal of Neurology, Neurosurgery & Psychiatry. 2008; 79(9):979–984.10.1136/jnnp.2007.136903
- Ball K, Berch DB, Helmers KF, Jobe JB, Leveck MD, Marsiske M, Willis SL. Effects of cognitive training interventions with older adults. Journal of the American Medical Association. 2002; 288:2271–2281. [PubMed: 12425704]
- Ball K, Owsley C. The Useful Field of View Test: A new technique for evaluating age-related declines in visual functioning. Journal of the American Optometric Association. 1993; 64:71–79. [PubMed: 8454831]
- Bickel H, Mösch E, Seigerschmidt E, Siemen M, Förstl H. Prevalence and persistence of mild cognitive impairment among elderly patients in general hospitals. Dementia and Geriatric Cognitive Disorders. 2006; 2:242–250. [PubMed: 16465052]
- Blazer DG, Hays JC, Fillenbaum GG, Gold DT. Memory complaint as a predictor of cognitive decline. Journal of Aging and Health. 1997; 9:171–184. [PubMed: 10182402]
- Brandt J. The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. The Clinical Neuropsychologist. 1991; 5:125–142.
- Brooks BL, Iverson GL, Holdnack JA, Feldman HH. Potential for misclassification of mild cognitive impairment: A study of memory scores on the Wechsler Memory Scale-III in healthy older adults. Journal of the International Neuropsychological Society. 2008; 14(3):463–478. [PubMed: 18419845]
- Brooks BL, Iverson GL, White T. Substantial risk of "accidential MCI" in health older adults: Base rates of low memory scores in neuropsychological assessment. Journal of the International Neuropsychological Society. 2007; 13:490–500. [PubMed: 17445298]

- Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC. Mild cognitive impairment: Prevalence and incidence according to difference diagnostic criteria: Results of the Leipzig Longitudinal Study of the Aged. British Journal of Psychiatry. 2003; 182:449–454. [PubMed: 12724250]
- Caracciolo B, Gatz M, Xu W, Pedersen NL, Fratiglioni L. Differential Distribution of Subjective and Objective Cognitive Impairment in the Population: A Nation-Wide Twin-Study. Journal of Alzheimer's Disease. 2012; 29(2):393–403.
- Cohen, J. Statistical power analysis for the behavioral sciences. 2. Hillsdale, NJ: Erlbaum; 1988.
- Cook SE, Marsiske M. Subjective memory beliefs and cognitive performance in normal and mildly impaired older adults. Aging and Mental Health. 2006; 10:413–423. [PubMed: 16798634]
- Cooney TM, Schaie KW, Willis SL. The relationship between prior functioning on cognitive and personality dimensions and subject attrition in longitudinal research. Journal of Gerontology. 1988; 43:12–17.
- Crowe M, Andel R, Wadley V, Cook S, Unverzagt F, Marsiske M, Ball K. Subjective cognitive function and decline among older adults with psychometrically defined amnestic MCI. International Journal of Geriatric Psychiatry. 2006; 21:1187–1192. [PubMed: 16955448]
- DeJager C, Blackwell AD, Budge MM, Sahakian BJ. Predicting cognitive decline in healthy older adults. American Journal of Geriatric Psychiatry. 2005; 13:735–740. [PubMed: 16085791]
- DeJager CA, Budge MM. Stability and predictability of the classification of mild cognitive impairment as assessed by episodic memory test performance over time. Neurocase. 2005; 11:72–79. [PubMed: 15804927]
- Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the nondemented elderly: Results from the Canadian Study of Health and Aging. Archives of Neurology. 1995; 52:612–619. [PubMed: 7763211]
- Ekstrom, RB.; French, JW.; Harman, H.; Derman, D. Kit of Factor Referenced Cognitive Tests-Revised Edition. Educational Testing Services; Princeton, NJ: 1976.
- Feldman HH, Jacova C. Mild Cognitive Impairment. American Journal of Geriatric Psychiatry. 2005; 13:645–655. [PubMed: 16085780]
- Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcome of mild cognitive impairment. Neurology. 2003; 61:1179–1184. [PubMed: 14610117]
- Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975; 12:189–198. [PubMed: 1202204]
- Ganguli M, Chang CCH, Snitz BE, Saxton JA, Vanderbilt J, Lee CW. Prevalence of Mild Cognitive Impairment by multiple classifications: The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) Project. American Journal of Geriatric Psychiatry. 2010; 18:674–683. [PubMed: 20220597]
- Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment amnestic type: An epidemiologic study. Neurology. 2004; 63:115–121. [PubMed: 15249620]
- Gonda, J.; Schaie, KW. Schaie-Thurstone Mental Abilities Test: Word Series Test. Consulting Psychologists Press; Palo Alto, CA: 1985.
- Goveas JS, Espeland MA, Woods NF, Wassertheil-Smoller S, Kotchen JM. Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: The Women's Health Initiative Memory Study. Journal of the American Geriatrics Society. 2011; 59:57–66. [PubMed: 21226676]
- Graham JE, Rockwood K, Beattie BL. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997; 349:1793–1796. [PubMed: 9269213]
- Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, Delis DC. Quantification of five neuropsychological approaches to defining mild cognitive impairment. American Journal of Geriatric Psychiatry. 2009; 17:368–375. [PubMed: 19390294]
- Jak AJ, Bangen KJ, Wierenga CE, Delano-Wood L, Corey-Bloom J, Bondi MW. Contributions of neuropsychology and neuroimaging to understanding clinical subtypes of mild cognitive impairment. International Review of Neurobiology. 2009b; 84:81–103. [PubMed: 19501714]
- Jorm AF, Christensen H, Korten AE, Henderson AS, Jacomb PA, Mackinnon A. Do cognitive complaints either predict future cognitive decline or reflect past cognitive decline? A longitudinal

study of an elderly community sample. Psychological Medicine. 1997; 27:91–98. [PubMed: 9122313]

- Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Dartigues JF. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002; 59:1594–1599. [PubMed: 12451203]
- Manly JJ, Bell-McGinty S, Tang MX, Schupf N, Stern Y, Mayeux R. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Archives of Neurology. 2005; 62:1739–1746. [PubMed: 16286549]
- Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JG, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Annals of Neurology. 2008; 63:494–506. [PubMed: 18300306]
- Marsiske, M.; Margrett, JA. Everyday problem solving and decision making. In: Birren, JE.; Schaie, KW., editors. Handbook of the Psychology of Aging. New York: Academic Press; 2006. p. 315-342.
- Morris JN, Fries BE, Steel K, Ikegami N, Bernabei R, Carpenter GI, Topinkova E. Comprehensive clinical assessment in community setting: Applicability of the MDS-HC. Journal of the American Geriatrics Society. 1997; 45:1017–1024. [PubMed: 9256857]
- Palmer K, Backman L, Winblad B, Fratiglioni L. Detection of Alzheimer's disease and dementia in the preclinical phase: Population based cohort study. British Medical Journal. 2003; 326:245–249. [PubMed: 12560271]
- Panza F, D'Introno A, Colaciccio AM, Capurso C, Del Parigi A, Caselli RJ, Solfrizzi V. Current epidemiology of mild cognitive impairment and other predementia syndromes. American Journal of Geriatric Psychiatry. 2005; 13:633–644. [PubMed: 16085779]
- Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Solfrizzi V. Late-life depression, mild cognitive impairment, and dementia: Possible continuum? American Journal of Geriatric Psychiatry. 2010; 18:98–116. [PubMed: 20104067]
- Petersen RC. Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologist. 1995; 1:326–344.
- Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine. 2004; 256:183–194. [PubMed: 15324362]
- Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangalos EG. Aging, memory, and mild cognitive impairment. International Psychogeriatrics. 1997; 9:65–69. [PubMed: 9447429]
- Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology. 1999; 56:303–308. [PubMed: 10190820]
- Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Wallace RB. Prevalence of cognitive impairment without dementia in the United States. Annals of Internal Medicine. 2008; 148:427–434. [PubMed: 18347351]
- Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement. 1977; 1:385–401.
- Rey A. L'examen psychologique dans les cas d'encephalopathie tramatique. Archives de Psychologie. 1941; 28:21.
- Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: A populationbased validation study. Neurology. 2001; 56:37–42. [PubMed: 11148233]
- Storandt M, Grant EA, Miller JP, Morris JC. Rates of Progression in Mild Cognitive Impairment and Early Alzheimer's Disease. Neurology. 2002; 59(7):1034–1041. [PubMed: 12370458]
- Tuokko, HA.; McDowell, I. An overview of mild cognitive impairment. In: Tuokko, HA.; Hultsch, DF., editors. Mild Cognitive Impairment: International Perspectives. New York: Taylor and Francis; 2006. p. 3-28.
- Unverzagt FW, Gao S, Baiyewu O, Ogunniyi AO, Gureje O, Perkins A, Hendrie HC. Prevalence of cognitive impairment: Data from the Indianapolis Study of Health and Aging. Neurology. 2001; 57:1655–1662. [PubMed: 11706107]

- Unverzagt FW, Guey LT, Jones RN, Marsiske M, King J, Wadley V, Tennstedt SL. ACTIVE Cognitive training and rates of incident dementia. Journal of the International Neuropsychological Society. 2012; 18:1–9. [PubMed: 22152338]
- Unverzagt FW, Ogunniyi A, Taler V, Gao S, Lane KA, Baiyewu O, Hall KS. Incidence and risk factors for Cognitive Impairment No Dementia and Mild Cognitive Impairment in African Americans. Alzheimer Disease and Associated Disorders. 2011; 25:4–10. [PubMed: 20921881]
- Unverzagt FW, Guey LT, Jones RN, Marsiske M, King JW, Wadley, Tennstedt SL. ACTIVE Cognitive Training and Rates of Incident Dementia. Journal of the International Neuropsychological Society. 201210.1017/S1355617711001470
- U.S. Census Bureau. Census 2000, Summary File 1; generated by Michael Marsiske; using American FactFinder. 2000. <a href="http://factfinder.census.gov">http://factfinder.census.gov</a>; (01 July 2011)
- Wadley VG, Crowe M, Marsiske M, Cook SE, Unverzagt FW, Rosenberg AL, Rexroth D. Changes in everyday function among individuals with psychometrically defined Mild Cognitive Impairment in the Advanced Cognitive Training for Independent and Vital Elderly Study. Journal of the American Geriatrics Society. 2007; 55:1192–1198. [PubMed: 17661957]
- Ware JE, Sherbourne CD. The MOS 36-Item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care. 1992; 30:473–483. [PubMed: 1593914]
- Wechsler, D. Manual for the Wechsler Adult Intelligence Scale—Revised. New York: The Psychological Corporation; 1981.
- Willis, SL.; Marsiske, M. Manual for the Everyday Problems Test. University Park, PA: Pennsylvania State University; 1993.
- Willis SL, Tennstedt SL, Marsiske M, Ball K, Elias J, Mann Koepke K, Wright E. Long-term effects of cognitive training on everyday functional outcomes in older adults. Journal of the American Medical Association. 2006; 296:2805–2814. [PubMed: 17179457]
- Wilson, B.; Cockburn, J.; Baddeley, A. The Rivermead Behavioural Memory Test. Thames Valley Test Company; Bury St. Edmunds, England: 1985.
- Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Petersen RC. Mild cognitive impairment- Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine. 2004; 256:240–246. [PubMed: 15324367]

### Appendix

7
~
=
<u> </u>
1.1
Τ
~
1
~
t
5
0
<b>-</b>
_
$\leq$
5
1
2
S
0

ਰੁੱ

**NIH-PA Author Manuscript** 

**NIH-PA Author Manuscript** 

	Stable Annestic (N=59)	Stable Non- amnestic (N=273)	Flipped Impairment (N=90)	Reverted to Unimpaired (N=304)	Worsened to Impaired (N=190)	Stable Unimpaired (N=1409)
A1 Age	74.66 (0.76) <sup>a</sup>	75.15 (0.35) <sup>a</sup>	$75.88 (0.61)^{a}$	75.82 (0.33) <sup>a</sup>	75.04 (0.42) <sup>a</sup>	75.20 (0.15) <sup>a</sup>
Years of Education	13.41 (0.35) <sup>a</sup>	$13.60 (0.16)^{a}$	$13.47(0.28)^{a}$	$13.58 (0.15)^a$	$13.80 (0.19)^{a}$	13.61 (0.07) <sup>a</sup>
Gender, %Female	61.02 (5.43)*	72.16 (2.53)*	48.89(4.40)*	78.29 (2.39)	75.79 (3.03)	79.91 (1.11)
Race, % African American	25.42 (5.55)	27.84 (2.58)	24.44 (4.50)	23.68 (2.45)	21.58 (3.95)	23.35 (1.14)
A1 Vision Score	71.52 (1.43) <sup>ab</sup>	70.65 (0.66) <sup>a</sup>	69.81 (1.16) <sup>a</sup>	$71.35 (0.63)^{abT}$	72.72 (0.80) <sup>ab</sup>	$73.36\ (0.29)^{\rm b}$
A1 MMSE $^{S}$		ı			ı	
A1 MMSE-No Language §		I			ı	
A1 CES-D	5.67 (0.67) <sup>ab</sup>	$6.12 (0.31)^{a}$	6.00 (0.54) <sup>ab</sup>	5.59 (0.23) <sup>ab</sup>	$5.84 (0.37)^{ab}$	4.77 (0.14) <sup>b</sup>
A1 SF-36 General Health	67.90 (2.61) <sup>ab</sup>	63.70 (1.20) <sup>a</sup>	62.63 (2.17) <sup>a</sup>	66.75 (1.15) <sup>ab</sup>	66.77 (1.47) <sup>ab</sup>	$69.59 (0.53)^{\rm b}$
A1 SF-36 Physical Functioning	65.42 (3.36) <sup>ab</sup>	61.93 (1.55) <sup>a</sup>	58.12 (2.73) <sup>a</sup>	65.82 (1.48) <sup>ab</sup>	64.31 (1.88) <sup>ab</sup>	$68.36\ (0.68)^{\rm b}$
A1 IADL/ADL	9.71 (1.02) <sup>ab</sup>	$6.84 (0.47)^{a}$	10.24 (0.82) <sup>b</sup>	$6.91 (0.44)^{a}$	7.48 (0.56) <sup>ab</sup>	4.85 (0.20) <sup>c</sup>
A5 Dropout %	30.51 (5.48)	31.50 (2.55)*	35.56 (4.44)*	29.61 (2.41)*	33.68 (3.05)*	18.59 (1.12)
Note: Matching superscript letters	indicate values are not signifi	cantly different, p>.05,	using Bonferroni corrected one-w	ay ANOVAs. Chi-squared	tests were used to meas	ure dichotomous variables

significant overall chi-square statistics were followed up with logistic contrasts, using the Stable Unimpaired group as the reference value; significant differences after adjusting for the 5 comparisons to the reference group are denoted with superscript\*. Trend-level significant difference from the Stable Unimpaired group, p < .10, is denoted with superscript<sup>T</sup>.

 $\S$ MMSE not administered at A1.

Cook et al.

.

_
_
~
_
_
<u> </u>
<b>U</b>
-
-
-
-
<u> </u>
-
-
_
-
$\mathbf{O}$
$\mathbf{U}$
_
_
-
~
0)
~
_
-
-
_
()
0,
0
_
_
0
_

.

## Appendix Table 2

Stability classifications from A1 to A2 and means (standard errors) of respective A2 outcomes (N=2,060)

	Stable Amnestic (N=54)	Stable Non- annestic (N=233)	Flipped Impairment (N=49)	Reverted to Unimpaired (N=180)	Worsened to Impaired (N=197)	Stable Unimpaired (N=1347)
A2 Age	76.87 (0.77) <sup>a</sup>	75.54 (0.37) <sup>a</sup>	$76.83 (0.81)^{a}$	75.47 (0.42) <sup>a</sup>	$76.83 (0.40)^{a}$	76.14 (0.15) <sup>a</sup>
Years of Education	12.91 (0.36) <sup>a</sup>	$13.88 (0.17)^a$	$13.00 (0.38)^{a}$	13.66 (0.20) <sup>a</sup>	$13.00 (0.19)^{a}$	$13.56\ (0.07)^{a}$
Gender, %Female	$66.67(5.71)^{\mathrm{T}}$	72.53 (2.75)*	55.10 (5.99)*	68.89 (3.13)*	55.10 (2.99)*	80.03 (1.14)
Race, % African American	24.07 (5.62)	23.61 (2.71)	32.65 (5.90)	20.00 (3.08)	32.65 (2.94)	21.38 (1.13)
A2 Vision Score	70.02 (1.69) <sup>ab</sup>	$69.91 (0.81)^a$	68.22 (1.77) <sup>ab</sup>	72.28 (0.93) <sup>ab</sup>	68.22 (0.88) <sup>ab</sup>	72.72 (0.34) <sup>b</sup>
A2 MMSE	23.74 (0.29) <sup>a</sup>	26.03 (0.15) <sup>b</sup>	$24.46(0.31)^{a}$	26.87 (0.17) <sup>c</sup>	26.58 (0.16) <sup>bc</sup>	27.76 (0.06) <sup>d</sup>
A2 MMSE-No Language	$16.34 (0.28)^{a}$	18.75(0.14) <sup>b</sup>	$17.28(0.29)^{a}$	$19.30(0.16)^{b}$	$19.04(0.15)^{b}$	$20.05(0.06)^{\circ}$
A2 CES-D	$6.69 (0.68)^{ m abcT}$	$6.19(0.33)^{ab}$	8.22 (0.72) <sup>a</sup>	5.66 (0.38) <sup>bc</sup>	8.22 (0.36) <sup>ab</sup>	$4.70 (0.14)^{c}$
A2 SF-36 General Health	65.78 (2.81) <sup>ab</sup>	64.02 (1.35) <sup>a</sup>	56.61 (2.96) <sup>a</sup>	65.62 (1.51) <sup>ab</sup>	$56.61 (1.48)^{a}$	69.76 (0.55) <sup>b</sup>
A2 SF-36 Physical Functioning	59.16 (3.66) <sup>ab</sup>	63.03 (1.75) <sup>ab</sup>	52.58 (3.85) <sup>a</sup>	62.96 (1.96) <sup>ab</sup>	52.58 (1.92)a <sup>b</sup>	66.87 (0.72) <sup>b</sup>
A2 IADL/ADL	$10.83 (0.94)^{a}$	6.93 (0.46) <sup>b</sup>	10.21 (1.01) <sup>a</sup>	6.87 (0.52) <sup>b</sup>	7.71 (0.51) <sup>ab</sup>	$4.81 (0.19)^{c}$
A5 Dropout %	27.78 (5.12)*	22.75 (2.47)*	32.65 (5.38)*	22.22 (2.81)*	32.65 (2.68)*	14.11 (1.03)
Note: Matching superscript letter	s indicate values are not signific	cantly different, p>.05,	using Bonferroni corrected one-way	ANOVAs. Chi-squar	ed tests were used to meas	ure dichotomous variables

significant overall chi-square statistics were followed up with logistic contrasts, using the Stable Unimpaired group as the reference value; significant differences after adjusting for the 5 comparisons to the reference group are denoted with superscript\*. Trend-level significant difference from the Stable Unimpaired group, p < .10, isdenoted with superscript<sup>T</sup>.

### Appendix Table 3

Stability classifications from A2 to A3 and means (standard errors) of respective A3 outcomes (N=1,943)

	Stable Amnestic (N=52)	Stable Non-amnestic (N=174)	Flipped Impairment (N=48)	Reverted to Unimpaired (N=201)	Worsened to Impaired (N=170)	Stable Unimpaired (N=1298)
A3 Age	80.38 (0.77) <sup>a</sup>	76.42 (0.42) <sup>b</sup>	$78.05 (0.80)^{ab}$	75.91 (0.39) <sup>b</sup>	77.53 (0.43) <sup>b</sup>	76.91 (0.15) <sup>b</sup>
Years of Education	$13.23 (0.37)^a$	13.75 (0.20) <sup>a</sup>	$13.88 (0.38)^{a}$	$13.98 (0.19)^{a}$	$13.46 (0.20)^{a}$	$13.56\ (0.07)^{a}$
Gender, %Female	69.23 (5.84)	72.41 (3.19)	56.25 (6.08)*	72.14 (2.97) <sup>T</sup>	68.24 (3.23)*	79.82 (1.17)
Race, % African American	25.00 (5.80)	28.16 (3.17)	29.17 (6.04)	19.90 (2.95)	25.29 (3.21)	21.65 (1.16)
A3 Vision Score	66.10 (1.76) <sup>a</sup>	$68.96 (0.96)^{a}$	$70.47 (1.84)^{ab}$	71.84 (0.90) <sup>ab</sup>	69.70 (0.98) <sup>ab</sup>	72.38 (0.35) <sup>b</sup>
A3 MMSE	23.53 (0.29) <sup>a</sup>	25.87 (0.16) <sup>bd</sup>	25.23 (0.32) <sup>b</sup>	27.27 (0.16) <sup>c</sup>	26.48 (0.16) <sup>d</sup>	27.83 (0.06) <sup>e</sup>
A3 MMSE-No Language	16.16 (0.27) <sup>a</sup>	18.57(0.15) <sup>bd</sup>	$18.00 (0.29)^{b}$	$19.59(0.15)^{c}$	19.19 (0.15) <sup>cd</sup>	20.07(0.06) <sup>€</sup>
A3 CES-D	7.07 (0.72) <sup>a</sup>	6.31 (0.39) <sup>a</sup>	5.92 (0.75) <sup>ab</sup>	$5.71 (0.36)^{abT}$	$6.02 (0.40)^{a}$	4.61 (0.14) <sup>b</sup>
A3 SF-36 General Health	59.63 (2.90) <sup>a</sup>	$63.75 (1.54)^{a}$	$63.80 (3.00)^{ab}$	68.12 (1.41) <sup>ab</sup>	63.94 (1.57) <sup>a</sup>	68.86 (0.55) <sup>b</sup>
A3 SF-36 Physical Functioning	58.09 (3.72) <sup>a</sup>	61.31 (1.98) <sup>a</sup>	57.21 (3.80) <sup>a</sup>	$68.04 (1.80)^{a}$	63.69 (2.00) <sup>a</sup>	66.37 (0.71) <sup>a</sup>
A3 IADL/ADL	11.69 (0.95) <sup>a</sup>	7.01 (0.52) <sup>b</sup>	$13.79 (0.98)^{a}$	6.71 (0.48) <sup>b</sup>	5.95 (0.53) <sup>bc</sup>	$4.89 (0.19)^{c}$
A5 Dropout %	30.77 (4.36)*	16.09(2.38)*	25.00 (4.54)*	5.97 (2.22)	22.35 (2.41)*	9.09 (0.87)
Note: Matching superscript letter significant overall chi-square sta	s indicate values are not signi istics werefollowed up with l	tficantly different, p>.05, using Boı ogistic contrasts, using the Stable I	nferroni corrected one-way ANOV Jnimpaired group as the reference	As. Chi-squared tes value; significant di	ts were used to mea fferences after adjus	sure dichotomous variables— ting for the 5 comparisons to the

reference group are denoted with superscript\*. Trend-level significant difference from the Stable Unimpaired group, p < .10, is denoted with superscript T.

<u> </u>
1
_
_
$\mathbf{a}$
_
_
~
$\geq$
01
L L
-
_
_
<u> </u>
10
0,
$\mathbf{n}$
$\mathbf{v}$
_
_
$\overline{\mathbf{n}}$
<u> </u>
-

NIH-PA

Cook et al.

### Appendix Table 4

Stability classifications from BL to A2 and means (standard errors) of respective A2 outcomes (N=2,173)

	Stable Amnestic (N=54)	Stable Non- amnestic (N=239)	Flipped Impairment (N=83)	Reverted to Unimpaired (N=279)	Worsened to Impaired (N=195)	Stable Unimpaired (N=1323)
A2 Age	77.33 (0.78) <sup>a</sup>	75.70 (0.37) <sup>a</sup>	76.88 (0.63) <sup>a</sup>	76.51 (0.34) <sup>a</sup>	76.44 (0.41) <sup>a</sup>	$75.90\ (0.16)^{a}$
Years of Education	13.07 (0.36) <sup>a</sup>	13.55 (0.17) <sup>a</sup>	$13.58 (0.29)^{a}$	$13.46 (0.16)^{a}$	$14.03 (0.19)^{a}$	$13.57 (0.07)^{a}$
Gender, %Female	64.81 (5.70)*	75.31 (2.71)	61.45 (4.60)*	73.12 (2.51)*	$72.82(3.00)^{\mathrm{T}}$	80.12 (1.15)
Race, % African American	24.07 (5.72)	25.94 (2.72)	32.53 (4.62)	20.79 (2.52)	20.00 (3.01)	22.68 (1.16)
A2 Vision Score	67.38 (1.70) <sup>a</sup>	$69.69 (0.81)^{a}$	70.31 (1.37) <sup>ab</sup>	71.60 (0.75) <sup>ab</sup>	71.85 (0.89) <sup>ab</sup>	72.89 (0.34) <sup>b</sup>
A2 MMSE	23.74 (0.30) <sup>a</sup>	25.80 (0.14) <sup>b</sup>	25.05 (0.25) <sup>b</sup>	27.04 (0.14) <sup>c</sup>	26.56 (0.16) <sup>c</sup>	27.76 (0.06) <sup>d</sup>
A2 MMSE-No Language	$16.38 (0.28)^{a}$	18.49 (0.14) <sup>b</sup>	17.68 (0.24) <sup>c</sup>	19.47 (0.13) <sup>d</sup>	19.08 (0.15) <sup>d</sup>	20.04 (0.06) <sup>€</sup>
A2 CES-D	$6.70 (0.69)^{abT}$	$6.58 (0.33)^{a}$	6.05 (0.56) <sup>ab</sup>	$5.63 (0.30)^{abT}$	$6.12 (0.36)^{a}$	4.72 (0.14) <sup>b</sup>
A2 SF-36 General Health	60.76 (2.90) <sup>a</sup>	64.04 (1.33) <sup>a</sup>	62.22 (2.29) <sup>a</sup>	65.91 (1.22) <sup>abT</sup>	64.49 (1.50) <sup>a</sup>	69.74 (0.56) <sup>b</sup>
A2 SF-36 Physical Functioning	56.96 (3.73) <sup>ab</sup>	62.57 (1.72) <sup>ab</sup>	56.20 (2.98) <sup>a</sup>	64.76 (1.58) <sup>ab</sup>	62.47 (1.95) <sup>ab</sup>	66.74 (0.72) <sup>b</sup>
A2 IADL/ADL	9.02 (0.96) <sup>ab</sup>	6.83 (0.45) <sup>ac</sup>	10.03 (0.77) <sup>b</sup>	$5.30~(0.41)^{\rm c}$	7.78 (0.51) <sup>ab</sup>	$4.98 (0.19)^{c}$
A5 Dropout %	22.22 (5.19)	22.59 (2.47)*	38.55 (4.19)*	19.71 (2.28)	20.00 (2.73)	15.04 (1.05)
Note: Matching superscript letters significant overall chi-square statis	indicate values are not signifi stics were followed up with lo	cantly different, p>.05, u gistic contrasts, using th	using Bonferroni corrected one-w e Stable Unimpaired group as the	ay ANOVAs. Chi-squared treference value; significar	tests were used to meas at differences after adju	ure dichotomous variables— ting for the 5 comparisons to the

reference group are denoted with superscript\*. Trend-level significant difference from the Stable Unimpaired group, p < .10, is denoted with superscript<sup>T</sup>.

~
~
_
_
_
_
_
~
-
-
_
_
<u> </u>
_
<b>_</b>
_
_
-
()
$\simeq$
-
$\geq$
-
0
-
_
_
_
<u> </u>
10
<sup>o</sup>
-
$\mathbf{O}$
~
_
5
<b>+</b>

.

### Appendix Table 5

Stability classifications from A1 to A3 and means (standard errors) of respective A3 outcomes (N=1,941)

	Stable Amnestic (N=54)	Stable Non- amnestic (N=179)	Flipped Impairment (N=40)	Reverted to Unimpaired (N=201)	Worsened to Impaired (N=177)	Stable Unimpaired (N=1290)
A3 Age	78.22 (0.81) <sup>ab</sup>	76.67 (0.42) <sup>ac</sup>	79.74 (0.91) <sup>bT</sup>	75.52 (0.39) <sup>c</sup>	77.84 (0.42) <sup>ab</sup>	77.06 (0.16) <sup>ab</sup>
Years of Education	12.91 (0.36) <sup>a</sup>	$13.69 (0.20)^{a}$	13.40 (0.42) <sup>a</sup>	$14.02 (0.19)^{a}$	$13.65 (0.20)^a$	$13.59 (0.07)^{a}$
Gender, %Female	66.67 (5.71)	67.04 (3.14)*	60.00 (6.64)*	72.64 (2.96)	76.84 (3.15)	79.77 (1.17)
Race, % African American	24.07 (5.71)	27.93 (3.14)	25.00 (6.63)	22.39 (2.96)	25.42 (3.15)	21.63 (1.17)
A3 Vision Score	68.96 (1.82) <sup>ab</sup>	$69.55 (0.94)^{ab}$	67.59 (2.05) <sup>ab</sup>	$73.33 (0.89)^a$	69.03 (0.95) <sup>b</sup>	72.28 (0.35) <sup>a</sup>
A3 MMSE	23.33 (0.34) <sup>a</sup>	26.05 (0.16) <sup>b</sup>	24.72 (0.35) <sup>a</sup>	27.25 (0.16) <sup>c</sup>	26.28 (0.16) <sup>b</sup>	27.80 (0.06) <sup>d</sup>
A3 MMSE-No Language	16.08 (0.31) <sup>a</sup>	$18.72(0.15)^{b}$	17.36 (0.32) <sup>a</sup>	19.53 (0.15) <sup>c</sup>	$19.08(0.15)^{\rm bc}$	20.05 (0.06) <sup>d</sup>
A3 CES-D	6.04 (0.75) <sup>ab</sup>	$6.43 (0.39)^{a}$	5.62 (0.84) <sup>ab</sup>	$5.10~(0.37)^{\rm ab}$	$5.60~(0.39)^{\rm ab}$	4.71 (0.14) <sup>b</sup>
A3 SF-36 General Health	63.36 (2.99) <sup>ab</sup>	63.12 (1.52) <sup>a</sup>	$59.83 (3.30)^{ab}$	69.22 (1.41) <sup>b</sup>	65.98 (1.54) <sup>ab</sup>	68.65 (0.55) <sup>b</sup>
A3 SF-36 Physical Functioning	57.95 (3.89) <sup>a</sup>	61.76 (1.98) <sup>a</sup>	$56.13 (4.30)^{a}$	$68.28 (1.84)^{a}$	62.41 (1.99) <sup>a</sup>	65.84 (0.72) <sup>a</sup>
A3 IADL/ADL	15.15 (1.05) <sup>a</sup>	7.39 (0.55) <sup>bc</sup>	11.19 (1.22) <sup>ab</sup>	6.58 (0.52) <sup>cdT</sup>	6.78 (0.55) <sup>c</sup>	4.97 (0.20) <sup>d</sup>
A5 Dropout %	27.78 (4.35)*	20.67 (2.39)*	45.00 (5.05)*	6.47 (2.25)	19.21 (2.40)*	9.22 (0.89)
Note: Matching superscript letter:	s indicate values are not signifi	cantly different, p>.05, t	sing Bonferroni corrected one-way	ANOVAs. Chi-squar	ed tests were used to meas	ure dichotomous variables

significant overall chi-square statistics were followed up with logistic contrasts, using the Stable Unimpaired group as the reference value; significant differences after adjusting for the 5 comparisons to the reference group are denoted with superscript\*. Trend-level significant difference from the Stable Unimpaired group, p < .10, is denoted with superscript<sup>\*</sup>.

~
~
_
_
_
_
_
~
-
-
_
_
<u> </u>
_
<b>_</b>
_
_
-
()
$\simeq$
-
$\geq$
-
0
-
_
_
_
<u> </u>
10
<sup>o</sup>
-
$\mathbf{O}$
~
_
5
<b>+</b>

# Appendix Table 6

Cook et al.

Stability classifications from A3 to A5 and means (standard errors) of respective A5 outcomes (N=1,738)

	Stable Amnestic (N=35)	Stable Non- amnestic (N=116)	Flipped Impairment (N=26)	Reverted to Unimpaired (N=170)	Worsened to Impaired (N=146)	Stable Unimpaired (N=1245)
A5 Age	80.51 (0.92) <sup>ab</sup>	78.37 (0.50) <sup>ab</sup>	79.33 (1.06) <sup>ab</sup>	78.36 (0.42) <sup>a</sup>	80.16 (0.45) <sup>b</sup>	78.28 (0.15) <sup>a</sup>
Years of Education	$12.94 (0.44)^{a}$	$13.34 (0.24)^{a}$	13.88 (0.52) <sup>a</sup>	$13.76 (0.20)^{a}$	$13.88 (0.22)^{a}$	$13.58 (0.07)^{a}$
Gender, %Female	65.71 (6.95)	78.45 (3.82)	$61.54 \ (8.07)^{\mathrm{T}}$	68.82 (3.16)*	71.23 (3.40)*	80.80 (1.17)
Race, % African American	40.00 (7.07)*	31.90 (3.88)*	26.92 (8.21)	22.94 (3.21)	28.77 (3.46)	20.72 (1.19)
A5 Vision Score	66.98 (2.18) <sup>ab</sup>	69.06 (1.20) <sup>ab</sup>	69.27 (2.53) <sup>ab</sup>	70.91 (0.99) <sup>ab</sup>	66.86 (1.07) <sup>a</sup>	72.19 (0.37) <sup>b</sup>
A5 MMSE	22.24 (0.38) <sup>a</sup>	25.31 (0.21) <sup>bd</sup>	24.31 (0.43) <sup>b</sup>	26.56 (0.19) <sup>c</sup>	25.77 (0.18) <sup>d</sup>	27.66 (0.07) <sup>e</sup>
A5 MMSE-No Language	15.06 (0.35) <sup>a</sup>	17.95(0.20) <sup>bd</sup>	$17.00(0.40)^{b}$	18.77(0.18) <sup>cd</sup>	$18.52(0.17)^{d}$	$19.91(0.06)^{\circ}$
A5 CES-D	6.95 (0.87) <sup>ab</sup>	7.13 (0.48) <sup>a</sup>	5.74 (1.01) <sup>ab</sup>	5.47 (0.39) <sup>ab</sup>	$5.95 (0.42)^{ab}$	4.92 (0.15) <sup>b</sup>
A5 SF-36 General Health	$57.97~(3.71)^{ m abT}$	63.05 (1.89) <sup>ab</sup>	56.48 (4.17) <sup>abT</sup>	64.75 (1.54) <sup>ab</sup>	62.65 (1.71) <sup>a</sup>	68.36 (0.57) <sup>b</sup>
A5 SF-36 Physical Functioning	55.17 (5.01) <sup>ab</sup>	54.56 (2.55) <sup>a</sup>	63.10 (5.62) <sup>ab</sup>	61.31 (2.07) <sup>ab</sup>	57.39 (2.30) <sup>ab</sup>	63.98 (0.77) <sup>b</sup>
A5 IADL/ADL	$13.03 (1.41)^{a}$	$9.23~(0.74)^{ab}$	7.88 (1.61) <sup>abc</sup>	7.07 (0.60) <sup>b</sup>	7.28 (0.67) <sup>b</sup>	4.91 (0.22) <sup>c</sup>
A5 Dropout %		T		Ţ	I	ı
Note: Matching superscript letters significant overall chi-square stati reference group are denoted with s	indicate values are not signifi stics were followed up with lo unberscript*. Trend-level signi	cantly different, p>.05, u gistic contrasts, using th ficant difference from th	Ising Bonferroni corrected one-way is Stable Unimpaired group as the re- te Stable Unimpaired group, $p < .10$	ANOVAs. Chi-squar ference value; signific , is denoted with supe	ed tests were used to meas cant differences after adju rscript T.	:ure dichotomous variables— sting for the 5 comparisons to the

### Appendix Table 7

Stability classifications from BL to A3 and means (standard errors) of respective A3 outcomes (N=2,045)

	Stable Amnestic (N=39)	Stable Non-amnestic (N=201)	Flipped Impairment (N=77)	Reverted to Unimpaired (N=279)	Worsened to Impaired (N=162)	Stable Unimpaired (N=1287)
A3 Age	78.90 (0.90) <sup>ab</sup>	76.63 (0.40) <sup>ab</sup>	78.10 (0.64) <sup>ab</sup>	77.12 (0.34) <sup>ab</sup>	78.19 (0.44) <sup>a</sup>	76.73 (0.16) <sup>b</sup>
Years of Education	13.00 (0.42) <sup>a</sup>	$13.65 (0.19)^{a}$	$13.65 (0.30)^{a}$	$13.45 (0.16)^{a}$	13.58 (0.21) <sup>a</sup>	$13.68 (0.07)^{a}$
Gender, %Female	69.23 (6.74)	72.64 (2.97) <sup>T</sup>	55.84 (4.79)*	73.84 (2.52)	70.99 (3.30)*	79.95 (1.17)
Race, % African American	28.21 (6.82)	32.34 (3.01)*	29.87 (4.86)	20.43 (2.55)	22.84 (3.35)	23.08 (1.19)
A3 Vision Score	66.31 (2.04) <sup>a</sup>	$68.51 (0.90)^{a}$	67.72 (1.45) <sup>a</sup>	71.21 (0.76) <sup>ab</sup>	70.22 (1.00) <sup>ab</sup>	72.71 (0.35) <sup>b</sup>
A3 MMSE	23.33 (0.34) <sup>a</sup>	25.89 (0.16) <sup>bd</sup>	25.06 (0.26) <sup>b</sup>	27.17 (0.14) <sup>c</sup>	26.31 (0.17) <sup>d</sup>	$27.83 (0.06)^{e}$
A3 MMSE-No Language	$16.03 (0.32)^{a}$	$18.59(0.14)^{\rm b}$	$17.73(0.24)^{c}$	19.47(0.13) <sup>d</sup>	19.09(0.16) <sup>bd</sup>	20.07(0.06) <sup>e</sup>
A3 CES-D	$5.06(0.83)^{ab}$	$6.45 (0.36)^{a}$	$6.74 \ (0.59)^{a}$	5.48 (0.31) <sup>ab</sup>	$5.98 (0.41)^{a}$	$4.63 (0.14)^{b}$
A3 SF-36 General Health	65.56 (3.32) <sup>ab</sup>	$(62.99 (1.44)^{a})$	62.45 (2.35) <sup>abT</sup>	66.22 (1.20) <sup>a</sup>	64.69 (1.64) <sup>a</sup>	69.15 (0.56) <sup>b</sup>
A3 SF-36 Physical Functioning	64.37 (4.29) <sup>a</sup>	60.71 (1.86) <sup>a</sup>	60.10 (3.03) <sup>a</sup>	66.79 (1.55) <sup>a</sup>	62.73 (2.10) <sup>a</sup>	66.10 (0.72 ) <sup>a</sup>
A3 IADL/ADL	8.27 (1.17) <sup>abcdT</sup>	$6.74 \ (0.51)^{ac}$	12.11 (0.82) <sup>b</sup>	5.69 (0.43) <sup>ad</sup>	7.80 (0.56) <sup>c</sup>	$5.01 (0.20)^{d}$
A5 Dropout %	20.51 (5.26)	17.41 (2.32)*	33.77 (3.74)*	8.96 (1.97)	24.69 (2.58)*	9.87 (0.92)
Note: Matching superscript letter significant overall chi-square sta	s indicate values are not signi tistics were followed up with	ificantly different, p>.05, using Boi logistic contrasts, using the Stable	nferroni corrected one-way ANOV Unimpaired group as the reference	As. Chi-squared tes value; significant d	ts were used to mea ifferences after adju	sure dichotomous variables— sting for the 5comparisons to the

reference group are denoted with superscript\*. Trend-level significant difference from the Stable Unimpaired group, p < .10, is denoted with superscript T.

~
~
_
<b>—</b>
_
- H
$\mathbf{r}$
~
~
<u> </u>
<b></b>
5
ō
_
-
~
-
0)
=
<u> </u>
~
0
0
÷
$\mathbf{\nabla}$
_

# Appendix Table 8

Cook et al.

Stability classifications from A2 to A5 and means (standard errors) of respective A5 outcomes (N=1,725)

	Stable Amnestic (N=28)	Stable Non- amnestic (N=114)	Flipped Impairment (N=42)	Reverted to Unimpaired (N=219)	Worsened to Impaired (N=136)	Stable Unimpaired (N=1186)
A5 Age	79.15 (1.02) <sup>abc</sup>	78.80 (0.51) <sup>ac</sup>	80.11 (0.83) <sup>ac</sup>	76.91 (0.37) <sup>b</sup>	79.99 (0.46) <sup>a</sup>	78.50 (0.16) <sup>c</sup>
Years of Education	$12.93 (0.50)^{a}$	13.96 (0.25) <sup>a</sup>	$13.48 (0.41)^{a}$	$13.95 (0.18)^{a}$	13.51 (0.23) <sup>a</sup>	$13.52 (0.08)^{a}$
Gender, %Female	60.71 (7.77) <sup>T</sup>	73.68 (3.85)	59.52 (6.34)*	73.52 (2.78) <sup>T</sup>	78.68 (3.52)	80.52 (1.19)
Race, % African American	35.71 (7.82)	28.07 (3.88)	$35.71 (6.39)^{\mathrm{T}}$	21.92 (2.80)	26.47 (3.55)	20.24 (1.20)
A5 Vision Score	66.13 (2.44) <sup>ab</sup>	69.39 (1.21) <sup>ab</sup>	66.81 (1.99) <sup>ab</sup>	71.34 (0.87) <sup>a</sup>	66.58 (1.10) <sup>b</sup>	72.13 (0.37) <sup>a</sup>
A5 MMSE	23.00 (0.43) <sup>a</sup>	25.25 (0.22) <sup>b</sup>	23.59 (0.35) <sup>a</sup>	26.90 (0.16) <sup>c</sup>	$25.80 (0.19)^{b}$	27.66 (0.07) <sup>d</sup>
A5 MMSE-No Language	$15.89 (0.40)^{a}$	17.87(0.21) <sup>b</sup>	$16.34(0.33)^{a}$	$19.16(0.15)^{c}$	$18.58(0.18)^{\rm bc}$	19.90(0.06)
A5 CES-D	$8.35\ (0.98)^{a}$	$6.60 (0.48)^{a}$	$6.64 (0.80)^{ab}$	$5.91 (0.35)^{abT}$	$6.48 (0.44)^{a}$	4.87 (0.15) <sup>b</sup>
A5 SF-36 General Health	$56.35 (4.17)^{abT}$	63.51 (1.91) <sup>a</sup>	57.21 (3.20) <sup>a</sup>	65.30 (1.36) <sup>ab</sup>	61.52 (1.78) <sup>a</sup>	68.46 (0.59) <sup>b</sup>
A5 SF-36 Physical Functioning	53.86 (5.61) <sup>ab</sup>	59.97 (2.56) <sup>ab</sup>	57.09 (4.25) <sup>ab</sup>	62.50 (1.83) <sup>a</sup>	53.34 (2.40) <sup>b</sup>	$64.02 (0.79)^{a}$
A5 IADL/ADL	12.84 (1.59) <sup>a</sup>	8.11 (0.75) <sup>ab</sup>	8.86 (1.23) <sup>ab</sup>	6.38 (0.54) <sup>bc</sup>	8.46 (0.71) <sup>ab</sup>	$5.00 (0.23)^{c}$
A5 Dropout %		I		I	ı	ı
Note: Matching superscript letters significant overall chi-square stati reference eroup are denoted with s	indicate values are not signifi stics were followed up with lo, superscript*. Trend-level signi	cantly different, p>.05, u gistic contrasts, using th ficant difference from th	ising Bonferroni corrected one-way e Stable Unimpaired group as the re e Stable Unimpaired group, v < .10	ANOVAs. Chi-squan ference value; signifi , is denoted with supe	ed tests were used to mea: cant differences after adju rscrint T.	sure dichotomous variables sting for the 5 comparisons to the

_
_
~
_
_
<u> </u>
<b>U</b>
-
-
-
<u> </u>
-
-
_
-
$\mathbf{O}$
$\mathbf{U}$
_
_
-
$\sim$
0)
~
_
-
-
_
()
0,
0
_
_
0
_

## Appendix Table 9

Stability classifications from A1 to A5 and means (standard errors) of respective A5 outcomes (N=1,714)

	Stable Annestic (N=30)	Stable Non- amnestic (N=114)	Flipped Impairment (N=32)	Reverted to Unimpaired (N=214)	Worsened to Impaired (N=135)	Stable Unimpaired (N=1189)
A5 Age	78.60 (0.98) <sup>abcd</sup>	78.17 (0.50) <sup>abd</sup>	79.76 (0.95) <sup>abcd</sup>	76.88 (0.37) <sup>b</sup>	80.88 (0.46) <sup>c</sup>	78.51 (0.16) <sup>d</sup>
Years of Education	$12.77 (0.48)^a$	13.76 (0.25) <sup>a</sup>	$13.75 (0.47)^{a}$	$13.83 (0.18)^a$	13.77 (0.23) <sup>a</sup>	$13.55 (0.08)^{a}$
Gender, %Female	56.67 (7.44)*	$71.05(3.82)^{\mathrm{T}}$	59.38 (7.21)*	74.77 (2.79)	82.22 (3.51)	80.74 (1.18)
Race, % African American	30.00 (7.64)	28.95 (3.92)	34.38 (7.40)	23.36 (2.86)	$29.63 (3.60)^{\mathrm{T}}$	20.77 (1.21)
A5 Vision Score	70.12 (2.36) <sup>ab</sup>	69.73 (1.21) <sup>ab</sup>	67.32 (2.29) <sup>ab</sup>	71.92 (0.88) <sup>a</sup>	65.26 (1.11) <sup>b</sup>	72.18 (0.38) <sup>a</sup>
A5 MMSE	23.28 (0.41) <sup>a</sup>	25.26 (0.22) <sup>b</sup>	$24.10~(0.40)^{ab}$	27.01 (0.16) <sup>c</sup>	25.73 (0.19) <sup>b</sup>	27.64 (0.07) <sup>d</sup>
A5 MMSE-No Language	$16.03 (0.38)^{a}$	18.01(0.20) <sup>b</sup>	$16.87(0.38)^{ab}$	$19.28(0.15)^{c}$	18.38(0.18) <sup>b</sup>	$19.88(0.06)^{d}$
A5 CES-D	7.01 (0.94) <sup>ab</sup>	7.02 (0.48) <sup>a</sup>	7.10 (0.91) <sup>ab</sup>	5.16 (0.35) <sup>b</sup>	$6.15 (0.44)^{ab}$	4.98 (0.15) <sup>b</sup>
A5 SF-36 General Health	58.56 (3.85) <sup>ab</sup>	62.32 (1.92) <sup>abT</sup>	57.03 (3.72) <sup>abT</sup>	67.08 (1.37) <sup>ab</sup>	61.79 (1.81) <sup>a</sup>	67.98 (0.59) <sup>b</sup>
A5 SF-36 Physical Functioning	59.12 (5.18) <sup>ab</sup>	56.71 (2.57) <sup>ab</sup>	$60.26~(5.00)^{ab}$	$63.91 (1.84)^a$	53.32 (2.44) <sup>b</sup>	63.52 (0.79) <sup>a</sup>
A5 IADL/ADL	12.39 (1.59) <sup>a</sup>	$8.77 (0.80)^{ab}$	$10.60 \ (1.53)^{ab}$	6.43 (0.57) <sup>bc</sup>	8.17 (0.75) <sup>ab</sup>	5.12 (0.24) <sup>c</sup>
A5 Dropout %				I	ı	1
Note: Matching superscript letters significant overall chi-square stati: reference group are denoted with s	indicate values are not signif stics were followed up with lc uperscript*. Trend-level sign	icantly different, p>.05, us ogistic contrasts, using the ificant difference from the	sing Bonferroni corrected one-way Stable Unimpaired group as the re s Stable Unimpaired group, p < .10.	ANOVAs. Chi-square erence value; signific is denoted with super	ed tests were used to mea: ant differences after adju rscript T.	ure dichotomous variables sting for the 5 comparisons to the

### Table 1

### Cognitive measures by domain

Domain	Test	Reliability*	Administration	Published Source
Memory	HVLT, Recall <sup>g</sup>	0.73 <sup>a</sup>	I *, W	Brandt, 1991
	AVLT, Recall <sup>g</sup>	0.78 <sup><i>a</i></sup>	G, W	Rey, 1941
	AVLT, Recognition	0.36 <sup>b</sup>	G, W	Rey, 1941
	RBMC, Paragraph Recall <sup>g</sup>	0.60 <sup>a</sup>	G, W	Wilson et al., 1985
Attention	Digit-Symbol Copy	0.62 <sup>C</sup>	1*, W*	Wechsler, 1981
	UFOV, task 1	0.69 <sup>d</sup>	I*, C*	Ball & Owsley 1993
Language	Vocabulary	0.87 <sup>e</sup>	G, W	Ekstrom French, Harman, & Derman, 1976
	MMSE language items $^{\$}$	-	1*, S*	Folstein, Folstein & McHugh, 1975
Visuospatial	UFOV, tasks 2/3 composite	0.78 <sup>e</sup>	I*, C*	Ball & Owsley, 1993
	Digit Symbol Substitution	$0.82^{f}$	1*, W*	Wechsler, 1981
Complex	Word Series	0.84 <sup>a</sup>	1*, W*	Gonda & Schaie,1985
	Everyday Problems Test	0.87 <sup>a</sup>	G*, W*	Willis & Marsiske, 1993

Note: Administration legend: I = individually administered, G = group administered, W = written responses, S = spoken (interviewer recorded) responses, C = computer administered test, \* asterisked administrations represent standard/usual conditions.

HVLT=Hopkins Verbal Learning Test; AVLT=Auditory Verbal Learning Test; RBMT=Rivermead Behavioural Memory Test; UFOV=Useful Field of View; MMSE=Mini-Mental Status Exam; Visuospatial=Visuospatial Processing Speed. Some memory tests were modified for group administration (AVLT, RBMT), and all memory tests employed audiotape administration, written responses by participants, and no delayed trials.

<sup>\*</sup>Reliabilities are all test-retest correlations;

 $^{\$}$ Items extracted from MMSE; published reliabilities not available;

<sup>*a*</sup>Ball et al., 2002;

<sup>b</sup>Schmitt, 2004;

<sup>c</sup>Calculated using ACTIVE control group, BL-1 Year;

<sup>d</sup>Edwards et al., 2005;

<sup>e</sup>Calculated using ACTIVE controlgroup, BL-Post test;

f Wechsler, 1981;

<sup>g</sup>No delayed recall list was given.

UFOV tasks: Task 1 required the participant to identify a target of either a truck or a car that is presented at a central fixation point on the screen. Tasks 2 and 3 were more complex as they required the participant to identify a target of either a truck or a car that is presented at a central fixation point on the screen as well as identify the location of a peripheral car that appeared in one of eight locations both without (Task 2) or with (Task 3) distracter triangles. Scores were recorded based on the minimum stimulus duration in which the participant responded correctly 75% of the time. **NIH-PA Author Manuscript** 

	A mnastic (N-776)	Non-Amnostic (N-703)	[[nimnoired (N-1873)	R-statistic/Dearson 2	ąĘ	oulov-n	Partial m <sup>2</sup>	Cohon's f
				L-Stausucht Carson A		h-value		
BL Age	75.15 (0.39) <sup>a</sup>	74.24 (0.22) <sup>ab</sup>	$73.96(0.14)^{b}$	4.31	2, 2799	0.014	0.003	0.055
Years of Education	$13.44 (0.18)^{a}$	$13.46\ (0.10)^{a}$	$13.57 (0.06)^{a}$	0.52	2, 2799	0.595	0.000	0.019
Female, n (%)	131 (57.96)*	$524 (74.54)^{\mathrm{T}}$	1471 (78.54)	$43.08^{+}$	2	<.001		·
African American, n (%)	55 (24.33)	199 (28.31)	474 (25.31)	2.71+	2	0.258		
BL Vision Score	70.32 (0.76) <sup>a</sup>	71.77(0.43) <sup>a</sup>	73.95 (0.26) <sup>b</sup>	16.63	2, 2799	<.001	0.012	0.110
BL CES-D	$6.33 (0.34)^{a}$	$6.18 (0.19)^{a}$	4.77 (0.12) <sup>b</sup>	25.15	2, 2799	<.001	0.018	0.135
BL MMSE	26.22 (0.13) <sup>a</sup>	26.60 (0.07) <sup>b</sup>	27.71 (0.04) <sup>c</sup>	129.4	4, 2797	<.001	0.085	0.305
BL MMSE-No Language	18.72 (0.12) <sup>a</sup>	19.27 (0.07) <sup>b</sup>	19.99 (0.04) <sup>c</sup>	76.38	4, 2797	<.001	0.052	0.234
BL SF-36 General Health	69.63 (1.20) <sup>ab</sup>	67.10 (0.67) <sup>a</sup>	$69.61 (0.41)^{b}$	5.21	4, 2747	0.006	0.004	0.063
BL SF-36 Physical Functioning	66.13 (1.55) <sup>a</sup>	67.47 (0.87) <sup>a</sup>	$69.59 (0.53)^{a}$	3.7	4, 2755	0.025	0.003	0.055
BL IADL/ADL	8.42 (0.42) <sup>a</sup>	6.70 (0.24) <sup>b</sup>	5.49 (0.15) <sup>c</sup>	26.1	4, 2797	<.001	0.018	0.135
Incident Dementia, n (%)	45 (20.6)*	72 (10.3)*	69 (3.7)	122.49	4	<.001		
Dropout by A5, n (%)	108 (47.79)*	284 (40.40)*	533 (28.46)	$57.23^{+}$	2	<.001	ı	ı
Reasons for Dropout								
Voluntary, n (%)	52 (23.01)*	144 (20.48)*	293 (15.64)	$13.45^{+}$	4	0.009		·
Involuntary, n (%)	23 (10.18)*	63 (8.96)*	107 (5.71)	$20.56^{+}$	4	<.001	,	
Death, n (%)	33 (14.60)*	77 (10.95)*	133 (7.08)	37.06+	4	<.001	ı	ı
Memory								
BL HVLT	18.41 (0.32) <sup>a</sup>	24.78 (0.18) <sup>b</sup>	27.46 (0.11) <sup>c</sup>	397.62	2, 2797	<.001	0.221	0.533
BL AVLT recall	33.39 (0.62) <sup>a</sup>	47.03 (0.35) <sup>b</sup>	50.82 (0.21) <sup>c</sup>	359.94	2, 2781	<.001	0.206	0.509
BL AVLT delayed recognition	10.38 (0.06) <sup>a</sup>	$11.56(0.04)^{b}$	11.72 (0.02) <sup>c</sup>	192.8	2, 2797	<.001	0.121	0.371
BL RBMT	3.55 (0.17) <sup>a</sup>	5.71 (0.10) <sup>b</sup>	6.82 (0.06) <sup>c</sup>	184.73	2, 2788	<.001	0.117	0.364
Attention								
<b>BL</b> Digit Symbol Copy	76.70 (1.41) <sup>a</sup>	$75.65 (0.80)^{a}$	$89.04 (0.49)^{\rm b}$	117.69	2, 2789	<.001	0.078	0.291
BL UFOV, task 1	36.82 (2.61) <sup>a</sup>	44.16 (1.48) <sup>b</sup>	25.00 (0.90) <sup>c</sup>	63.06	2, 2786	<.001	0.043	0.212
Language								
Vocabulary	$10.97 (0.24)^{a}$	$10.20(0.14)^{b}$	$13.37 (0.08)^{c}$	209.83	2, 2789	<.001	0.131	0.388

	Amnestic (N=226)	Non-Amnestic (N=703)	Unimpaired (N=1873)	F-statistic/Pearson $\chi^2$	df	p-value	Partial $\eta^2$	Cohen's f
MMSE language items	7.49 (0.04) <sup>a</sup>	7.33 (0.02) <sup>b</sup>	7.73 (0.01) <sup>c</sup>	122.06	2, 2797	<.001	0.080	0.295
Visuospatial								
UFOV, task 2/3 composite	570.72 (13.82) <sup>a</sup>	554.57 (7.84) <sup>a</sup>	404.18 (4.79) <sup>b</sup>	169.09	2, 2786	<.001	0.108	0.348
Digit Symbol Substitution	$34.24 (0.66)^{a}$	$34.57 (0.38)^{a}$	43.28 (0.23) <sup>b</sup>	237.13	2, 2791	<.001	0.145	0.412
Complex								
Word Series	6.98 (0.30) <sup>a</sup>	7.09 (0.17) <sup>a</sup>	10.70 (0.10) <sup>b</sup>	205.87	2, 2796	<.001	0.128	0.383
Everyday Problems Test	$15.39 (0.34)^{a}$	$15.94 (0.19)^a$	20.06 (0.12) <sup>b</sup>	208.33	2, 2787	<.001	0.130	0.387

Note: BL=Baseline; CES-D= Center for Epidemiological Studies-Depression-12;MMSE=Mini-Mental Status Exam; SF-36= MOS Short Form Health Survey; IADL/ADL=Instrumental Activities of Daily Living/Activities of Daily Living:HVLT=Hopkins Verbal Learning Test; AVLT=Auditory Verbal Learning Test; RBMT=Rivermead Behavioural Memory Test; UFOV=Useful Field of View; Visuospatial=Visuospatial Processing Speed

denoted with superscript<sup>+</sup>. Significant overall chi-square statistics were followed up with logistic contrasts, using the Unimpaired group as the reference value; significant differences after adjusting for the 2 comparisons to the reference group are denoted with superscript\*. Trend-level significant difference from the Unimpaired group, p < .10, is denoted with superscript<sup>T</sup>. Valuesafter CES-D (indicated by a Matching superscript letters indicate values are not significantly different, p>.05, using Bonferoni corrected one-way ANOVAs. Chi-squared tests were used to measure dichotomous variables and are horizontal line) are after covarying for BL Vision and Depression.

### Table 3

Baseline raw impairment numbers(percent)by cognitive domain.

	Single Domain	Multidomain-amnestic	Multidomain-non-amnestic
Memory (N-206)	03 (41 2%)	133 (58 8%)	
MICHINE A LAND	(0/7.11) ((		I
Attention (N=192)	52 (27.1%)	30 (15.6%)	110 (57.3%)
Language (N=409)	216 (52.8%)	59 (14.4%)	134 (32.8%)
Visucenstial (N-786)	1702 201 20	1700 SC/ VL	134 (46 0%)
v isuuspanai (iv=200)	(0% C. 17) 01	(0% 6.07) +1	(0,6.04) 104
Complex (N=376)	128 (34.0%)	85 (22.6%)	163 (43.4%)

Note: The percentage corresponds to the proportion of people with that particularimpairment (e.g., memory) classified as either single domain, multidomain amnestic or multidomain non-amnestic.; Visuospatial=Visuospatial Processing Speed.

	Stabla Amnatia (N_34)	Stable Non-	Dirrod Transiend (N-67)	Reverted to Unimpaired	Worsened to	Stable Hainmin M-1103)	E statistic Doguson 2.2+	Ĵ	oulor a	Doutiol 22	ուս Մշետո՞ն ք
	(17-14) ANSAULTE ALARA		rupped unpairment (14-07)		(crr-v) no meduur	(7/11-VI) no mediumo orang	T PLAUDUCT CALIBOR Y	m	p-value	1 a1 man 1	
A5 Age	$78.46(1.11)^{ab}$	78.76 (0.47) <sup>ab</sup>	80.44 (0.67) <sup>b</sup>	77.78 (0.33) <sup>a</sup>	$80.19 (0.51)^{b}$	$78.38 (0.16)^{a}$	5.07	5, 1805	<.001	0.014	0.119
Years of Education	12.63 (0.54) <sup>a</sup>	13.72 (0.22) <sup>a</sup>	13.19 (0.32) <sup>a</sup>	$13.44 (0.16)^{a}$	13.93 (0.25) <sup>a</sup>	$13.62 (0.08)^{a}$	1.62	5, 1805	.153	0.004	0.063
Female, n (%)	16 (66.67)	106 (77.37)	38 (56.72)*	207 (75.00)	91 (79.13)	964 (80.87)	$26.96^+$	5	<.001		
African American, n (%)	7 (29.17)	45 (32.85)*	21 (31.34)	61 (22.10)	35 (30.43)	261 (21.90)	$14.30^{+}$	5	.014		
A5 Vision Score	67.97 (2.65) <sup>abc</sup>	68.45 (1.11) <sup>ab</sup>	$67.83 (1.59)^{\rm abcT}$	$70.82 \ (0.78)^{\rm ac}$	66.48 (1.21) <sup>b</sup>	72.29 (0.38) <sup>c</sup>	7.19	5, 1805	<.001	0.020	0.143
A5 MMSE	23.17 (0.47) <sup>a</sup>	25.27 (0.20) <sup>b</sup>	23.92 (0.29) <sup>a</sup>	26.86 (0.15) <sup>c</sup>	25.89 (0.21) <sup>b</sup>	27.66 (0.07) <sup>d</sup>	75.44	5, 1588	<.001	0.192	0.487
A5 MMSE-No Language	$16.04 (0.44)^{a}$	$17.96(0.19)^{b}$	16.77 (0.27) <sup>a</sup>	19.13 (0.14) <sup>c</sup>	$18.53 (0.20)^{bc}$	19.91 (0.07) <sup>d</sup>	59.13	5, 1588	<.001	0.157	0.432
A5 CES-D	7.10 (1.05) <sup>ab</sup>	$6.27 \ (0.44)^{abT}$	$7.12 (0.63)^{a}$	5.65 (0.31) <sup>ab</sup>	$6.65 (0.48)^{a}$	4.91 (0.15) <sup>b</sup>	6.40	5, 1805	<.001	0.017	0.132
A5 SF-36 General Health	$56.95 (4.60)^{ab}$	64.57 (1.75) <sup>ab</sup>	58.41 (2.57) <sup>a</sup>	65.65 (1.21) <sup>ab</sup>	$60.33 (1.95)^{a}$	68.30 (0.59) <sup>b</sup>	7.06	5, 1753	<.001	0.020	0.143
A5 SF-36 Physical Functioning	59.87 (6.20) <sup>abc</sup>	58.64 (2.36) <sup>abc</sup>	53.05 (3.43) <sup>ab</sup>	62.72 (1.63) <sup>bc</sup>	53.22 (2.63) <sup>a</sup>	63.73 (0.79) <sup>c</sup>	5.01	5, 1757	<.001	0.014	0.119
A5 IADL/ADL	10.67 (1.83) <sup>ab</sup>	7.71 (0.73) <sup>a</sup>	12.68 (1.06) <sup>b</sup>	$(0.09 (0.50)^{ac})$	$8.11 (0.80)^{a}$	5.09 (0.24) <sup>c</sup>	14.49	5, 1783	<.001	0.039	0.201

followed up with logistic contrasts, using the Stable Unimpaired group as the reference value; significant differences after adjusting for the 5 comparisons to the reference groupare denoted with superscript\*. Trend-level significant difference from the Stable Unimpaired group, p Matching superscript letters indicate values are not significantly different, p>.05, using Bonferroni corrected one-way ANOVAs. Chi-squared tests were used to measure dichotomous variables and are denoted with superscript<sup>+</sup>. Significant overall chi-square statistics were <.10, is denoted with superscript<sup>T</sup>.

**NIH-PA Author Manuscript** 

Stability classifications from BL to A5 and means (standard errors) of respective A5 outcomes (N=1,811)